Occudo Quantitative Strategies’s Pacira BioSciences PCRX Stock Holding History

Occudo Quantitative Strategies’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-51,874	Closed	-$2M	–	1125
2022 Q4	$2M	Buy	51,874 +47,037	+972%	+$2.29M	0.23%	128
2022 Q3	$257K	Buy	+4,837	New	+$269K	0.02%	898
2022 Q2	–	Sell	-5,902	Closed	-$450K	–	1323
2022 Q1	$450K	Sell	5,902 -1,663	-22%	-$111K	0.04%	687
2021 Q4	$455K	Sell	7,565 -7,559	-50%	-$417K	0.04%	648
2021 Q3	$847K	Buy	15,124 +3,416	+29%	+$197K	0.1%	355
2021 Q2	$710K	Buy	+11,708	New	+$741K	0.11%	311

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Occudo Quantitative Strategies's PCRX Position: Q1 2023 in Review

Occudo Quantitative Strategies sold out of Pacira BioSciences (PCRX) in Q1 2023, closing a stake of 51,874 shares — an estimated $2M sold.

Occudo Quantitative Strategies first reported a position in PCRX in Q2 2021 and held it in 6 quarters. The position peaked at $2M in Q4 2022. 267 funds tracked by Wall St. Rank hold PCRX as of Q1 2023.

Occudo Quantitative Strategies reported no remaining Pacira BioSciences position as of Q1 2023 after selling out during the quarter.
Occudo Quantitative Strategies sold 51,874 Pacira BioSciences shares in Q1 2023, an estimated $2M.
Occudo Quantitative Strategies first reported a position in Pacira BioSciences in Q2 2021 and held it in 6 quarters.
Occudo Quantitative Strategies's Pacira BioSciences position peaked at $2M in Q4 2022.
267 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2023.

Based on Occudo Quantitative Strategies's 13F filing for Q1 2023, filed 15 May 2023.